Gilead Sciences: Pipeline Progress & Regulatory Milestones As A Pivotal Growth Lever! 

Gilead Sciences Inc. delivered a strong performance in the fourth quarter and full year 2024, with significant revenue growth driven by its core business areas despite facing some industry-specific and macroeconomic challenges. Positives from the earnings results include a robust increase in product sales, excluding Veklury (remdesivir), demonstrating an 8% year-over-year growth, reaching $26.8 billion. The primary driver was the HIV portfolio, which exceeded expectations with an 8% growth to $19.6 billion for the year, led by the leading HIV treatment, Biktarvy, which saw a 13% increase in sales. This highlights Gilead’s strong position in the HIV market and its ability to execute successfully in a competitive space. The HIV prevention market also showed accelerated growth, setting the stage for the anticipated U.S. launch of lenacapavir, an innovative treatment in this category.